MET and non-small cell lung carcinoma: Our rate of clinically relevant “true” high-level MET amplification (4.4%) using FISH is similar to the observed rate in the study by Okuda et al., where they obtained a rate of 5,6% MET gene amplified cases of n = 213 NSCLC patients [35].